Mikael Lindström1, Niina Tohmola2, Risto Renkonen3, Esa Hämäläinen4, Camilla Schalin-Jäntti5, Outi Itkonen2. 1. HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: mikael.lindstrom@hus.fi. 2. HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 3. HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Haartman Institute, University of Helsinki, Helsinki, Finland. 4. HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland. 5. Endocrinology, Abdominal Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Abstract
BACKGROUND: Serotonin (5-hydroxytyramine) is a mediator of gastrointestinal smooth muscle contraction, and is secreted by neuroendocrine neoplasms (NENs). We developed a liquid chromatography tandem mass spectrometry (LC-MS/MS) assay for serum serotonin to be used in NEN diagnostics and follow-up. METHODS: We used serum samples from healthy volunteers (n = 31) and patients suspected or monitored for NEN (n = 98). Serotonin-D4 internal standard was added to samples before solid phase extraction (SPE) and quantification by LC-MS/MS. The effects of sample handling and preparation on serotonin stability were studied. Finally, we established a provisional reference range for serum serotonin and compared our assay with serum 5-hydroxyindoleacetic acid (5-HIAA) for detection of NENs. RESULTS: Our assay is sensitive and has a wide linear range (10-10,000 nmol/l). Serum serotonin is stable for 7 days at room temperature and for 3 months at -20 °C. Sampling temperature is not critical. Normal range for serum serotonin was 270-1490 nmol/l. We found that serum serotonin and 5-HIAA performed equally well as diagnostic tests for NENs. CONCLUSIONS: Our LC-MS/MS assay for serum serotonin is well suited for clinical research and patient diagnostics. Our results confirm that it can complement 5-HIAA in diagnosis of NENs.
BACKGROUND:Serotonin (5-hydroxytyramine) is a mediator of gastrointestinal smooth muscle contraction, and is secreted by neuroendocrine neoplasms (NENs). We developed a liquid chromatography tandem mass spectrometry (LC-MS/MS) assay for serum serotonin to be used in NEN diagnostics and follow-up. METHODS: We used serum samples from healthy volunteers (n = 31) and patients suspected or monitored for NEN (n = 98). Serotonin-D4 internal standard was added to samples before solid phase extraction (SPE) and quantification by LC-MS/MS. The effects of sample handling and preparation on serotonin stability were studied. Finally, we established a provisional reference range for serum serotonin and compared our assay with serum 5-hydroxyindoleacetic acid (5-HIAA) for detection of NENs. RESULTS: Our assay is sensitive and has a wide linear range (10-10,000 nmol/l). Serum serotonin is stable for 7 days at room temperature and for 3 months at -20 °C. Sampling temperature is not critical. Normal range for serum serotonin was 270-1490 nmol/l. We found that serum serotonin and 5-HIAA performed equally well as diagnostic tests for NENs. CONCLUSIONS: Our LC-MS/MS assay for serum serotonin is well suited for clinical research and patient diagnostics. Our results confirm that it can complement 5-HIAA in diagnosis of NENs.
Authors: Maria J Reimann; Merete Fredholm; Signe E Cremer; Liselotte B Christiansen; Kathryn M Meurs; Jacob E Møller; Jens Häggström; Jens Lykkesfeldt; Lisbeth H Olsen Journal: J Vet Intern Med Date: 2021-10-02 Impact factor: 3.333
Authors: Nikos Papadimitriou; Marc J Gunter; Neil Murphy; Audrey Gicquiau; David Achaintre; Stefanie Brezina; Tanja Gumpenberger; Andreas Baierl; Jennifer Ose; Anne J M R Geijsen; Eline H van Roekel; Andrea Gsur; Biljana Gigic; Nina Habermann; Cornelia M Ulrich; Ellen Kampman; Matty P Weijenberg; Per Magne Ueland; Rudolf Kaaks; Verena Katzke; Vittorio Krogh; Bas Bueno-de-Mesquita; Eva Ardanaz; Ruth C Travis; Matthias B Schulze; Maria-José Sánchez; Sandra M Colorado-Yohar; Elisabete Weiderpass; Augustin Scalbert; Pekka Keski-Rahkonen Journal: Int J Cancer Date: 2021-07-12 Impact factor: 7.396